156 related articles for article (PubMed ID: 27904742)
1. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.
Aït Moussa L; El Bouazzi O; Serragui S; Soussi Tanani D; Soulaymani A; Soulaymani R
Ther Adv Drug Saf; 2016 Dec; 7(6):239-247. PubMed ID: 27904742
[TBL] [Abstract][Full Text] [Related]
2. Correlations among the plasma concentrations of first-line anti-tuberculosis drugs and the physiological parameters influencing concentrations.
Cheng L; Luo M; Guo Y; Fan Y; Wang P; Zhou G; Qin S; Weng B; Li P; Liu Z; Liu S
Front Pharmacol; 2023; 14():1248331. PubMed ID: 37869746
[No Abstract] [Full Text] [Related]
3. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
Ramachandran G; Hemanth Kumar AK; Kannan T; Thangakunam B; Shankar D; Christopher DJ
Indian J Med Res; 2023; 157(2&3):211-215. PubMed ID: 36861539
[TBL] [Abstract][Full Text] [Related]
5. Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
Kumar AKH; Chandrasekaran V; Kannan T; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2018 Mar; 147(3):287-292. PubMed ID: 29923518
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
7. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of genotype MTBDRplus assay for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis clinical isolates from Pakistan.
Javed H; Jamil N; Jagielski T; Bakuła Z; Tahir Z
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S147-S148. PubMed ID: 28043516
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
12. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
Um SW; Lee SW; Kwon SY; Yoon HI; Park KU; Song J; Lee CT; Lee JH
Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974
[TBL] [Abstract][Full Text] [Related]
13. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
Marra F; Marra CA; Bruchet N; Richardson K; Moadebi S; Elwood RK; Fitzgerald JM
Int J Tuberc Lung Dis; 2007 Aug; 11(8):868-75. PubMed ID: 17705952
[TBL] [Abstract][Full Text] [Related]
14. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
15. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
17. Smartly Engineered PEGylated Di-Block Nanopolymeric Micelles: Duo Delivery of Isoniazid and Rifampicin Against Mycobacterium tuberculosis.
Rani S; Gothwal A; Khan I; Pachouri PK; Bhaskar N; Gupta UD; Chauhan DS; Gupta U
AAPS PharmSciTech; 2018 Oct; 19(7):3237-3248. PubMed ID: 30191379
[TBL] [Abstract][Full Text] [Related]
18. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
[TBL] [Abstract][Full Text] [Related]
19. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
Avachat AM; Bhise SB
Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
Chung SJ; Byeon SJ; Choi JH
J Korean Med Sci; 2022 Apr; 37(16):e128. PubMed ID: 35470602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
